WO1999050411A3 - Tumour-specific expression control region and the use thereof - Google Patents

Tumour-specific expression control region and the use thereof Download PDF

Info

Publication number
WO1999050411A3
WO1999050411A3 PCT/EP1999/002031 EP9902031W WO9950411A3 WO 1999050411 A3 WO1999050411 A3 WO 1999050411A3 EP 9902031 W EP9902031 W EP 9902031W WO 9950411 A3 WO9950411 A3 WO 9950411A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumour
control region
expression control
specific expression
gene
Prior art date
Application number
PCT/EP1999/002031
Other languages
French (fr)
Other versions
WO1999050411A2 (en
Inventor
Reinhard Buettner
Anja-Katrin Bosserhoff
Stefan Seeber
Georg Tiefenthaler
Ruediger Rueger
Original Assignee
Roche Diagnostics Gmbh
Reinhard Buettner
Bosserhoff Anja Katrin
Stefan Seeber
Georg Tiefenthaler
Ruediger Rueger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics Gmbh, Reinhard Buettner, Bosserhoff Anja Katrin, Stefan Seeber, Georg Tiefenthaler, Ruediger Rueger filed Critical Roche Diagnostics Gmbh
Priority to AU35991/99A priority Critical patent/AU3599199A/en
Publication of WO1999050411A2 publication Critical patent/WO1999050411A2/en
Publication of WO1999050411A3 publication Critical patent/WO1999050411A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

An expression vector containing a gene which codes for a transcription or translation product which is therapeutically active, wherein this gene is under the control of an expression control region having the sequence SEQ ID NO:1 or a fragment thereof which comprises at least the bases bp -224 to -214 and/or -197 to -207 from SEQ ID NO:1 is tumour-cell-specific and suitable for in vivo and in vitro ablation or regression of tumour cells.
PCT/EP1999/002031 1998-03-27 1999-03-25 Tumour-specific expression control region and the use thereof WO1999050411A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU35991/99A AU3599199A (en) 1998-03-27 1999-03-25 Tumour-specific expression control region and the use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98105614A EP0945507A1 (en) 1998-03-27 1998-03-27 Tumor specific expression controll region and its use
EP98105614.6 1998-03-27

Publications (2)

Publication Number Publication Date
WO1999050411A2 WO1999050411A2 (en) 1999-10-07
WO1999050411A3 true WO1999050411A3 (en) 2000-03-02

Family

ID=8231663

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/002031 WO1999050411A2 (en) 1998-03-27 1999-03-25 Tumour-specific expression control region and the use thereof

Country Status (3)

Country Link
EP (1) EP0945507A1 (en)
AU (1) AU3599199A (en)
WO (1) WO1999050411A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2226414T3 (en) 1998-06-10 2005-03-16 Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh STIMULATION OF THE IMMUNE SYSTEM
EP1133988A1 (en) * 2000-03-11 2001-09-19 Biognostik Gesellschaft für biomolekulare Diagnostik mbH Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene
EP1133994A1 (en) * 2000-03-11 2001-09-19 Biognostik Gesellschaft für biomolekulare Diagnostik mbH A method for reversing the immunosuppressive effects of the Melanoma Inhibitory Activity "MIA"
GB0015371D0 (en) * 2000-06-23 2000-08-16 Novartis Res Found Tumour-cell specific gene expression and its use in cancer therapy
ES2289544T3 (en) * 2003-08-12 2008-02-01 Antisense Pharma Gmbh OLIGONUCLEOTIDO ANTISENTIDO TO INHIBIT THE INHIBITING ACTIVITY OF MELANOMA MIA.
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000446A1 (en) * 1991-06-27 1993-01-07 Genelabs Technologies, Inc. Screening assay for the detection of dna-binding molecules
WO1995003328A2 (en) * 1993-07-20 1995-02-02 Boehringer Mannheim Gmbh Melanoma-inhibiting protein
WO1995015972A1 (en) * 1993-12-09 1995-06-15 Thomas Jefferson University Compounds and methods for site-directed mutations in eukaryotic cells
WO1996034969A2 (en) * 1995-05-03 1996-11-07 Canji, Inc. Gene therapy using replication competent targeted adenoviral vectors
US5578444A (en) * 1991-06-27 1996-11-26 Genelabs Technologies, Inc. Sequence-directed DNA-binding molecules compositions and methods
WO1996039841A1 (en) * 1995-06-07 1996-12-19 Georgetown University Tumor- or cell-specific herpes simplex virus replication

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000446A1 (en) * 1991-06-27 1993-01-07 Genelabs Technologies, Inc. Screening assay for the detection of dna-binding molecules
US5578444A (en) * 1991-06-27 1996-11-26 Genelabs Technologies, Inc. Sequence-directed DNA-binding molecules compositions and methods
WO1995003328A2 (en) * 1993-07-20 1995-02-02 Boehringer Mannheim Gmbh Melanoma-inhibiting protein
WO1995015972A1 (en) * 1993-12-09 1995-06-15 Thomas Jefferson University Compounds and methods for site-directed mutations in eukaryotic cells
US5565350A (en) * 1993-12-09 1996-10-15 Thomas Jefferson University Compounds and methods for site directed mutations in eukaryotic cells
WO1996034969A2 (en) * 1995-05-03 1996-11-07 Canji, Inc. Gene therapy using replication competent targeted adenoviral vectors
WO1996039841A1 (en) * 1995-06-07 1996-12-19 Georgetown University Tumor- or cell-specific herpes simplex virus replication

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BOSSERHOFF A.K. ET AL: "Regulation of melanoma-specific expression of the MIA gene by distinct promoter elements", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 39, March 1998 (1998-03-01), WASHINGTON US, pages 250, XP002087909 *
BOSSERHOFF A-K ET AL.: "Melanoma-specific activity of the MIA promoter", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 37, no. 0, March 1996 (1996-03-01), WASHINGTON US, pages 521, XP002087911 *
BOSSERHOFF A-K ET AL: "Structure and promoter analysis of the gene encoding the human melanoma-inhibiting protein MIA", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 1, 1996, MD US, pages 490 - 495, XP002087912 *
LEDERER M ET AL.: "Analysis of the promoter elements responsible for melanoma specific expression of MIA", JOURNAL OF DERMATOLOGICAL SCIENCE, vol. 16, no. Suppl.1, March 1998 (1998-03-01), US, pages S48, XP002087910 *

Also Published As

Publication number Publication date
AU3599199A (en) 1999-10-18
WO1999050411A2 (en) 1999-10-07
EP0945507A1 (en) 1999-09-29

Similar Documents

Publication Publication Date Title
AU6871398A (en) Method for enhancing expression of a foreign or endogenous gene product in pla nts
AU2001290837A1 (en) Use of a polypeptide comprising the extracellular domains of il-20rb for the treatment of inflammation
WO1994001548A3 (en) Human nucleic acid fragments, isolated from brain adrenal tissue, placenta or bone narrow
WO1996007734A3 (en) Recombinant adenovirus comprising a chimeric penton base protein
EP2284189A3 (en) Nucleic acid molecules encoding fibroblast growth factor-like (FGF-like) polypeptides
CA2213343A1 (en) Chimeric adenoviral fiber protein and methods of using same
WO1990013306A3 (en) Small polypeptides
WO1999053061A3 (en) Tumor associated nucleic acids and uses therefor
EP2258383A3 (en) Antigenic peptides derived from telomerase
EP1553182A3 (en) Regulated genes and uses thereof
WO2000063246A3 (en) Compounds and methods for modulating beta-catenin mediated gene expression
WO1998028317A3 (en) Synthesis of nucleosides and polynucleotides
WO2001044480A3 (en) Enzymes and genes used for producing vanillin
EP0828003A3 (en) Human serine protease
IL135688A0 (en) Human checkpoint kinase, hcds1, compositions and methods
WO2000050588A3 (en) Genes associated with diseases of the colon
WO1997022695A3 (en) Nucleotide sequences, proteins, drugs and diagnostic agents for treating cancer
WO1999050411A3 (en) Tumour-specific expression control region and the use thereof
AU2164197A (en) Recombinant adenoviral vectors for human tumour gene therapy
CA2226889A1 (en) An expression control sequence for general and effective expression of genes in plants
CA2305655A1 (en) Self-deleting vectors for cancer therapy
WO2002092758A8 (en) Gastrokines and derived peptides including inhibitors
CA2197075A1 (en) Method of Gene Therapy Using DNA Vectors Without Selection Marker Gene
AU1720397A (en) Recombinant expression of s-layer proteins
UA26870C2 (en) The method for increasing of protein c production, the method for increasing of modification level thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA